As per MRFR analysis, the US GERD and NERD Treatment Market Size was estimated at 413.7 (USD Million) in 2023. The US GERD and NERD Treatment Market Industry is expected to grow from 453.6(USD Million) in 2024 to 982 (USD Million) by 2035. The US GERD and NERD Treatment Market CAGR (growth rate) is expected to be around 7.274% during the forecast period (2025 - 2035).
The US GERD and NERD treatment market is witnessing significant trends driven by lifestyle changes and increased awareness of gastrointestinal health. One of the key market drivers is the rising prevalence of gastroesophageal reflux disease (GERD) in the United States, which can be attributed to factors such as obesity, dietary preferences, and sedentary lifestyles.
According to health data from credible sources, the growing population of older adults is also a significant contributor, as age increases the risk of esophageal disorders. The demand for effective treatments has led to advancements in medication and minimally invasive surgical options, expanding treatment modalities available for patients.
In recent times, there has been a notable shift towards telemedicine and digital health solutions for managing GERD and NERD, especially post-pandemic. This trend not only enhances patient access to healthcare but also improves the ongoing management of chronic conditions, allowing for timely adjustments to treatment plans based on real-time data.
There is also a growing emphasis on preventive care and lifestyle modification programs, as healthcare providers recognize the importance of addressing the root causes of GERD. Additionally, the burgeoning interest in plant-based diets and natural remedies offers opportunities for new product development within the market.
As consumers increasingly seek personalized treatment plans, companies are encouraged to explore developments in biomarkers and genetic biomarkers that allow for tailored therapies. The US GERD and NERD treatment market is positioned at a crossroads, with both challenges and opportunities that industry players can leverage to meet evolving patient needs while navigating regulatory frameworks.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The growing prevalence of Gastroesophageal Reflux Disease (GERD) and Non-Erosive Reflux Disease (NERD) in the United States is a significant driver for the US GERD and NERD Treatment Market Industry. According to the American College of Gastroenterology, GERD affects about 20% of the U.S. population.
Moreover, research indicates an increase in prevalence rates in recent years, with some studies reporting that approximately 30% of adults in the U.S.experience GERD symptoms at least once a month. This rise in incidence is attributed to lifestyle factors such as obesity, sedentary behavior, and dietary habits, which are prevalent in the U.S.
These trends indicate a growing need for effective treatment options, thereby fueling market growth. Additionally, established organizations like the American Gastroenterological Association are actively promoting awareness about GERD and associated treatment options, further driving demand in the US GERD and NERD Treatment Market Industry.
The US GERD and NERD Treatment Market Industry is significantly driven by advancements in treatment options. Recent innovations, including the development of novel medications and minimally invasive surgical procedures, are gaining traction. The U.S. Food and Drug Administration (FDA) has approved several new drug formulations aimed at enhancing therapeutic outcomes for GERD patients, leading to improved patient adherence and satisfaction.
A study published in Gastroenterology found that novel PPI (Proton Pump Inhibitor) formulations improved symptom control in up to 80% of patients, promising a more effective management strategy.Improvements in surgical techniques, such as the transoral incisionless fundoplication, are presenting effective alternatives for patients who do not respond to medications. This progress encourages healthcare providers to adopt these innovations, thereby expanding the market.
The increasing healthcare expenditure in the United States represents a crucial driver for the US GERD and NERD Treatment Market Industry. According to the Centers for Medicare and Medicaid Services (CMS), national health spending is projected to grow at an average rate of 5.4% annually between 2020 and 2028, emphasizing the expansion of healthcare access and treatment options available for chronic conditions like GERD and NERD.
This rise in expenditure not only reflects a commitment to improved healthcare infrastructure but also underscores a growing consumer demand for advanced EGDs (esophagogastroduodenoscopies) and treatments leading to better disease management.With organizations such as the American Medical Association advocating for increased healthcare funding and reimbursement, emphasis on managing chronic illnesses becomes paramount, subsequently driving the US GERD and NERD Treatment Market Industry.
The Drug Class segment within the US GERD and NERD Treatment Market has been pivotal in addressing the rising prevalence of gastroesophageal reflux diseases. This segment encompasses a range of medications, including Antacids, Proton Pump Inhibitors (PPIs), and H2 Receptor Blockers, each playing a vital role in managing symptoms associated with GERD and NERD.
Antacids, known for their quick action in neutralizing stomach acid, have been a go-to for immediate relief of heartburn and indigestion, making them highly favored among patients seeking over-the-counter solutions.Proton Pump Inhibitors represent a significant portion of the market due to their ability to provide long-lasting acidity control by inhibiting proton pumps in the stomach lining.
Their effectiveness in treating erosive esophagitis and preventing complications of GERD has led to their preferred status among healthcare providers. H2 Receptor Blockers, while slightly overshadowed by PPIs in terms of market share, still hold importance in chronic management, particularly for those who may not tolerate PPIs or require alternative therapies.
Trends in the market indicate a growing preference for PPIs given their efficacy, contributing to their strong foothold in the therapeutic landscape.However, the rise in awareness regarding potential long-term side effects associated with prolonged PPI use has spurred interest in alternative treatments and resulted in more balanced utilization between these drug classes.
Additionally, advancements in formulation technologies and the development of innovative delivery systems have the potential to enhance the effectiveness of these drug classes, thus further influencing the US GERD and NERD treatment landscape. The overall market dynamics reflect significant growth opportunities driven by an aging population, increasing dietary changes, and a rise in obesity, all contributing to the surge in GERD and NERD cases across the United States.
As healthcare professionals and patients continue to seek effective treatment options, understanding the nuances within the Drug Class segment becomes critical for navigating the evolving trends of the US GERD and NERD Treatment Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US GERD and NERD Treatment Market, particularly within the Dosage Form segment, showcases a clear delineation between Solid and Liquid forms of medication. Solid dosage forms, such as tablets and capsules, are often favored due to their convenience and longer shelf life, making them a predominant choice among patients and healthcare providers.
Meanwhile, Liquid forms cater to specific patient needs, including those who have difficulty swallowing pills or require rapid absorption of medication. This flexibility in dosage options is crucial, as it enhances patient compliance and allows for tailored treatment approaches.
As the US faces increasing prevalence rates of GERD and NERD, driven by rising obesity levels and lifestyle factors, the demand for diverse dosage forms continues to grow. The focus on innovative formulations in either dosage type presents opportunities for market players to develop products that effectively address patient needs, improving health outcomes while also depicting trends that align with growing health awareness in the region.
This segmentation ultimately reflects a growing understanding of the importance of medication accessibility and the need for personalizing treatment plans in the US healthcare landscape.
The US GERD and NERD Treatment Market is characterized by its diverse End User landscape, which includes Hospitals, Clinics, Research Centers, and Others. Hospitals play a pivotal role in the treatment of gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD) due to their comprehensive medical facilities and access to specialist physicians.
Clinics also serve a significant purpose in outpatient care, providing quick and effective treatments for patients. Research Centers contribute to the advancement of treatment methodologies through clinical trials and innovation, fostering a deeper understanding of GERD and NERD.
Other platforms encompass a range of healthcare providers that participate in the management of these conditions. With an increasing incidence of GERD and NERD in the US, driven by lifestyle factors and an aging population, these End Users are positioned to address a growing demand for effective management and treatment options.
Overall, the segmentation highlights the importance of healthcare infrastructure in ensuring optimal patient outcomes and the necessity for continuous research and development in this field.
The US GERD and NERD Treatment Market has been witnessing significant growth driven by rising incidences of gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD). This increase in prevalence has fostered a competitive landscape that is characterized by ongoing product innovations, strategic partnerships, and an expanding range of treatment options.
Pharmaceutical companies are heavily investing in research and development to introduce more effective medications and therapies that cater to the needs of patients suffering from these conditions. With healthcare professionals seeking to improve therapeutic outcomes, the market dynamics are continuously evolving as companies strive to capture a larger share of this lucrative segment.
Moreover, factors such as increasing healthcare expenditure, enhanced patient awareness, and favorable reimbursement policies are contributing to the overall growth of the market.
AstraZeneca has established a robust presence in the US GERD and NERD Treatment Market, primarily focusing on its innovative therapeutic solutions. The company is known for its commitment to addressing the unmet needs of patients suffering from digestive disorders with a portfolio that encompasses effective antacid and proton pump inhibitor medications.
AstraZeneca leverages its strong research capabilities and collaborative partnerships to drive its market leadership further. The organization benefits from a solid reputation for quality and reliability in its product offerings, which positions it favorably against competitors. Its strategic initiatives aimed at enhancing patient outcomes, along with a strong distribution network in the US, reinforce its competitive advantage while ensuring product accessibility for a diverse patient population.
Novartis, another key player in the US GERD and NERD Treatment Market, continues to demonstrate a strong commitment to innovation and patient-centered solutions. The company's portfolio includes a variety of gastroenterology treatments that are designed to provide effective relief for GERD and NERD patients.
Novartis maintains a significant market presence through its focus on research and development, continuously striving to enhance existing therapies and introduce new ones. The company is recognized for its strategic mergers and acquisiations, which have bolstered its product lineup and expanded its reach in the US market. By leveraging its strong research capabilities and commitment to improving patient care, Novartis has managed to establish itself as a formidable competitor in this rapidly evolving landscape, addressing the needs of patients with advanced and effective therapeutic options.
The US GERD and NERD Treatment Market has seen significant developments recently, particularly with leading companies like AstraZeneca, Merck, and Pfizer actively engaged in innovations and product launches. In September 2023, AstraZeneca announced positive results from a clinical trial for a new medication aiming to enhance treatment efficacy for GERD patients, thereby impacting market dynamics.
Furthermore, in August 2023, Merck received FDA approval for an updated formulation of their popular GERD treatment, boosting market share. Current affairs also highlight the growing interest in telehealth solutions as patients increasingly seek remote consultations for GERD management. Ironwood Pharmaceuticals and Takeda Pharmaceuticals are at the forefront, exploring digital platforms for patient engagement.
On the mergers and acquisitions front, in July 2023, Amgen acquired a smaller biotech company specializing in gastrointestinal therapies, strengthening its portfolio in the GERD treatment sector. Additionally, Johnson and Johnson announced a strategic collaboration in June 2023 with a digital health company to enhance patient adherence to GERD treatments.
This evolving landscape marks a robust growth trajectory for the US GERD and NERD Treatment Market, with established firms working to address the rising prevalence of gastrointestinal disorders.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 413.7(USD Million) |
| MARKET SIZE 2024 | 453.6(USD Million) |
| MARKET SIZE 2035 | 982.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.274% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | AstraZeneca, Novartis, Merck, Eli Lilly, Endo International, Takeda Pharmaceuticals, Boehringer Ingelheim, Pfizer, Ironwood Pharmaceuticals, Amgen, AbbVie, Roche, Sanofi, Johnson and Johnson, GSK |
| SEGMENTS COVERED | Drug Class, Dosage Form, End User |
| KEY MARKET OPPORTUNITIES | Innovative drug development, Digital health solutions, Telehealth services expansion, Personalized medicine approaches, Rising awareness and education |
| KEY MARKET DYNAMICS | Increasing prevalence of obesity, Rising awareness and diagnosis, Advancements in treatment options, Growing geriatric population, Shift towards minimally invasive procedures |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US GERD and NERD Treatment Market is expected to be valued at approximately 982.0 million USD by 2035.
In 2024, the US GERD and NERD Treatment Market was valued at around 453.6 million USD.
The market is expected to grow at a compound annual growth rate (CAGR) of 7.274% from 2025 to 2035.
Proton Pump Inhibitors hold the highest market value in 2024, valued at 250.0 million USD.
By 2035, the market value of Antacids is projected to reach 200.0 million USD.
Key players in the market include AstraZeneca, Novartis, Merck, Eli Lilly, and Takeda Pharmaceuticals.
The market for H2 Receptor Blockers is expected to be valued at 232.0 million USD by 2035.
Emerging trends include the increasing use of innovative drug formulations and the rising demand for personalized medicine.
Key growth drivers include the increasing prevalence of gastrointestinal disorders and advancements in treatment options.
Regional factors such as healthcare infrastructure and access to treatment significantly influence market growth across different areas.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
